TBC Bristol-Myers Squibb Australia Pty Ltd
Product name
TBC
Accepted date
Jan-2024
Active ingredients
nivolumab
Proposed indication
For the treatment of patients with unresectable or metastatic urothelial carcinoma.
Application type
C (new indication)
Publication date
Jan-2024